- Trial Phase
- Pre-approval biosimilar (351(k)) development — analytical comparability stage; no active Phase 2/3 trial in local data a
- Time to Market
- Unknown — several years at best. The program is still in FDA pathway-alignment (Type 2a meeting held Jan 2026; Type 2b planned 2H26); a BLA has not been filed and five-year milestone warrants are tied to Phase 3 trial initiation, so US approval is likely late-2020s or later if the biosimilar path succeeds.
- Why 4/10
- ABP-450 is AEON's only drug candidate, but the next hard catalyst is an FDA Type 2b alignment meeting planned for 2H26 (minutes of which trigger expiry of the two-year milestone warrants), not a PDUFA or pivotal readout — with no BLA filed and Phase 3 not yet initiated, no binary approval catalyst exists in the next ~12 months, capping the score at 5 despite near-total single-asset concentration.
Treat the ~$6.70 two-analyst price target as a stale artifact set before the July 2026 re-IPO dilution (stock trades ~$0.26, near its 52-week low of $0.222). Watch the FDA Type 2b meeting in 2H26 — its minutes trigger expiry of the two-year milestone warrants and could unlock up to $34M in additional gross proceeds, a potential double-edged catalyst: capital in, but at heavy dilution. Also monitor NYSE American compliance status after the August 3, 2026 deadline to regain listing standards.
Price Chart
Executive Summary
ABP-450 is AEON Biopharma's (NYSE American: AEON) only disclosed drug candidate — a botulinum toxin type A developed as a biosimilar to BOTOX for full-label US therapeutic use. The program is early-stage on the regulatory pathway (FDA Type 2a meeting done, Type 2b planned 2H26, no BLA filed, Phase 3 not started), while the company is a distressed, pre-revenue microcap: FY2025 net loss of $39.2M, a ~$55M stockholders' deficit, a NYSE American delisting notice, and a massively dilutive July 2026 financing (17.85M shares + 24.84M pre-funded + 85.38M milestone warrants at ~$0.32/unit). Net read: bearish — no near-term binary catalyst, heavy dilution and listing risk dominate the story.
How It Works
Botulinum toxin type A is a purified protein that temporarily blocks nerve signals to overactive muscles, relaxing them — the same mechanism as BOTOX. ABP-450 is being developed as a 'biosimilar' (a near-copy designed to be highly similar to BOTOX) so AEON can enter the US market with BOTOX's full therapeutic label — all 12 FDA-approved indications such as cervical dystonia, chronic migraine and spasticity — typically priced at a discount to the originator.
Trial Status
ABP-450 is being advanced as a biosimilar to BOTOX (onabotulinumtoxinA) for full-label US therapeutic entry. FDA Type 2a meeting held Jan 21, 2026 to align the analytical pathway; company reported positive FDA feedback and analytical similarity to BOTOX (FY2025 report, Mar 30, 2026) and presented structural/functional comparability data at the American Headache Society meeting June 4, 2026. Type 2b meeting planned for 2H26.
The Two-Sided Case
Upcoming Catalysts
- FDA Type 2b meeting planned for 2H26 — receipt of meeting minutes triggers expiry of the two-year milestone warrants and may unlock additional warrant proceeds
- Milestone-warrant-driven financing (potential ~$34.0M additional gross proceeds) tied to FDA/clinical milestones for ABP-450
- NYSE American continued-listing status update after the Aug 3, 2026 compliance deadline
- Q3 2026 earnings (cash-runway update) and any ABP-450 regulatory-pathway news
- Possible reverse split or further dilutive financing if share price stays below $1
Source Filing
The SecBot filing or press-release report that triggered this drug report:
AEON Biopharma, Inc. 424B4 AEON ·Originating report